News/Publications
Plain Language Summary of the Innovate Study: Ibrutinib Plus Rituximab Is Well-Tolerated and Effective in People with Waldenström's Macroglobulinemia
Buske, C., A. Tedeschi, J. Trotman, R. García-Sanz, D. MacDonald, V. Leblond, B. Mahe, C. Herbaux, J. V. Matous, C. S. Tam, L. T. Heffner, M. Varettoni, M. L. Palomba, C. Shustik, E. Kastritis, S. P. Treon, J. Ping, B. Hauns, I. Arango-Hisijara, and M. A. Dimopoulos.
Future Oncol (Feb 23 2023).
Born in the Uk: A Registry to Improve and Broadcast Knowledge on Waldenström Macroglobulinaemia
Durot, E. and A. Delmer.
Br J Haematol (Feb 16 2023).
Clinical Intergroup
Clinical Intergroup
The ECWM is based on a clinical intergroup connecting all major clinical national study groups such as:
- BNLI
- Czech Myeloma Group
- FIL Italian Intergroup
- FCGCLLWM Group
- GLA/OSHO
- Greek Myeloma Study Group
- HOVON
- Nordic Lymphoma Group
- Portuguese Lymphoma Study Group
- Spanish Study Group
The ECWM is associated with the Australasian Leukaemia & Lymphoma Goup (ALLG). This clinical intergroup forms a unique platform for setting up large clinical and innovative trials in a rare disease such as WM.
Currently several clinical trials are initiated which offer patients with WM novel therapeutic approaches in the setting of well controlled clinical trials.